175 related articles for article (PubMed ID: 23665201)
1. Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth.
Halasi M; Pandit B; Wang M; Nogueira V; Hay N; Gartel AL
Am J Pathol; 2013 Jul; 183(1):257-65. PubMed ID: 23665201
[TBL] [Abstract][Full Text] [Related]
2. FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.
Pandit B; Gartel AL
Cell Cycle; 2011 Oct; 10(19):3269-73. PubMed ID: 21941087
[TBL] [Abstract][Full Text] [Related]
3. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
Uddin S; Hussain AR; Ahmed M; Siddiqui K; Al-Dayel F; Bavi P; Al-Kuraya KS
Haematologica; 2012 Jul; 97(7):1092-100. PubMed ID: 22271891
[TBL] [Abstract][Full Text] [Related]
6. A new target for proteasome inhibitors: FoxM1.
Gartel AL
Expert Opin Investig Drugs; 2010 Feb; 19(2):235-42. PubMed ID: 20074015
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
8. FoxM1, a critical regulator of oxidative stress during oncogenesis.
Park HJ; Carr JR; Wang Z; Nogueira V; Hay N; Tyner AL; Lau LF; Costa RH; Raychaudhuri P
EMBO J; 2009 Oct; 28(19):2908-18. PubMed ID: 19696738
[TBL] [Abstract][Full Text] [Related]
9. ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors.
Halasi M; Wang M; Chavan TS; Gaponenko V; Hay N; Gartel AL
Biochem J; 2013 Sep; 454(2):201-8. PubMed ID: 23772801
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
12. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
[TBL] [Abstract][Full Text] [Related]
13. Targeting FOXM1 in cancer.
Halasi M; Gartel AL
Biochem Pharmacol; 2013 Mar; 85(5):644-652. PubMed ID: 23103567
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
16. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.
Sourbier C; Valera-Romero V; Giubellino A; Yang Y; Sudarshan S; Neckers L; Linehan WM
Cell Cycle; 2010 Oct; 9(20):4183-9. PubMed ID: 20953139
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Lee SR; Ko TH; Youm JB; Kim N; Ko KS; Rhee BD; Han J
Exp Mol Med; 2013 Oct; 45(10):e50. PubMed ID: 24158003
[TBL] [Abstract][Full Text] [Related]
19. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Du ZX; Zhang HY; Meng X; Guan Y; Wang HQ
BMC Cancer; 2009 Feb; 9():56. PubMed ID: 19216805
[TBL] [Abstract][Full Text] [Related]
20. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells.
Bhat UG; Halasi M; Gartel AL
PLoS One; 2009; 4(5):e5592. PubMed ID: 19440351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
